Skip to main content
NewslettersWatchlist

Aclaris Therapts(ACRS-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low1.1650
Day High1.2100
Open:1.2000
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
BayStreet.ca
Biotech Sector Advances in Pancreatic Cancer Research
Motley Fool
Why Aclaris Therapeutics Stock Soared Nearly 6% on Thursday
Motley Fool
2 Low-Priced Stocks That Could Make You Richer
Motley Fool
Why Aclaris Therapeutics Topped the Market on Tuesday
Motley Fool
These 2 Biotech Stocks Made Big Monday Moves
Motley Fool
Why Aclaris Therapeutics Is Crashing Today
PR Newswire
Eric Gulve Announces Retirement as President of BioSTL Startup Arm BioGenerator; Charlie Bolten to Take the Helm
Motley Fool
10 Best Stocks to Buy Now in December
Globe Newswire
Aclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
Globe Newswire
Aclaris Therapeutics Expands Leadership Team
Globe Newswire
Aclaris Therapeutics to Participate in the Jefferies Healthcare Conference
Globe Newswire
Aclaris Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
Globe Newswire
Aclaris Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
Globe Newswire
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
Globe Newswire
Aclaris Therapeutics to Participate in the SVB Leerink Virtual 11th Annual Global Healthcare Conference
Globe Newswire
Aclaris Therapeutics Expands Leadership Team
Globe Newswire
Aclaris Therapeutics Provides R&D Update
Globe Newswire
Aclaris Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference
Globe Newswire
Aclaris Therapeutics Announces Publication of Preclinical Research of Zunsemetinib in Pancreatic Cancer in Science Translational Medicine
Globe Newswire
Aclaris Therapeutics to Host Virtual R&D Day on December 7, 2021
Globe Newswire
Aclaris Therapeutics to Participate in Upcoming Investor Conferences
Globe Newswire
Aclaris Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update
Globe NewsWire
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Aclaris Therapeutics, Inc. โ€“ ACRS
Globe NewsWire
Aclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative Action
Globe NewsWire
Aclaris Therapeutics to Participate in Upcoming Investor Conferences
Globe NewsWire
Aclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
Globe NewsWire
Aclaris Therapeutics to Participate in the William Blair Biotech Focus Conference 2021
Globe NewsWire
Aclaris Announces Pricing of Public Offering of Common Stock
Globe NewsWire
Aclaris Announces Proposed Public Offering of Common Stock
Globe NewsWire
Aclaris Therapeutics Announces Positive Preliminary Topline Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis
Globe NewsWire
Aclaris Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
Globe NewsWire
Aclaris Therapeutics Reports First Quarter 2021 Financial Results and Provides a Corporate Update

Profile

Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright ยฉ 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright ยฉ 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.